Starling/CRRT Observational Study

Baxter Healthcare Corporation

Overview

Hemodynamic optimization of critically ill patients is a goal for clinicians in order to afford the patient the best possible outcomes. Being able to precisely and rapidly determine patient fluid responsiveness provides the bedside physician and nursing staff the information needed to make critical decisions in regard to the patient's fluid status and management of additional fluids and medications. As fluid management and cardiac output determination are linked to better decision-making and improved outcomes in ICU, the use of a dynamic assessment of fluid responsiveness becomes a key tool for patient management. This study is designed to collect treatment and outcome data on patients that have undergone hemodynamic monitoring during CRRT therapy.

Study Type

OBSERVATIONAL

Conditions

Hemodynamic Monitoring

Interventions

StarlingDEVICE

Starling is a portable, non-invasive, cardiac output detector system. The Starling monitor measures the cardiac output by employing electrical bioreactance. Bioreactance is a measure of the electrical characteristics of a volume of tissue and fluid. In the case of cardiac output measurements, the relevant tissue includes the heart and the immediate surrounding volume of the thorax. The relevant fluid is blood. The Starling electrode is a double electrode sensor. Within each sensor, one electrode is used to transmit a high frequency sine wave into the body, while the resulting voltage is measured at the adjacent electrode. This information is used to determine cardiac output. The Starling monitor also measures and displays associated hemodynamic parameters based on calculations of measurements already incorporated into the Starling monitor.

Eligibility

Sex: ALLMin age: 18 YearsMax age: 95 Years

Medical Language ↔ Plain English

Inclusion Criteria: 1. ≥18 to 95 years of age. 2. Patient has undergone hemodynamic monitoring with the Starling monitor during a CRRT treatment. 3. Hemodynamic monitoring was completed no earlier than 2018 Exclusion Criteria: 1. Patients did not have an arterial line in place during CRRT treatment 2. Patients on extracorporeal membrane oxygenation (ECMO) or left ventricular assist device (LVAD) 3. Patients with end-stage kidney disease on chronic dialysis 4. Hemodynamic monitoring with Starling did not occur during CRRT treatment 5. Data from Starling, CRRT machine, or arterial line cannot be retrieved

Locations (1)

Baxter Investigational Site

Lexington, Kentucky, United States